

Evaluation of Homocysteine Levels in Patients with Polycystic Ovarian Syndrome

Saghar Salehpour, M.D.*, Ozra Manzor-al-ajdad, M.D.,
Elham Neisani Samani, M.D., Alireza Abadi, M.Sc.

1. Department of Obstetric and Gynecology, Infertility and Reproductive Health Research Center (IRHRC),
Shahid Beheshti University (Mc.S), Tehran, Iran

Abstract

Background: To determine the level of plasma homocysteine in patients with polycystic ovary syndrome (PCOS) compared with healthy controls.

Materials and Methods: In this prospective case-control study on 85 PCOS women and 83 controls matched by body mass index (BMI), homocysteine levels were assessed.

Results: The mean level of homocysteine was 16.25 ± 11.94 $\mu\text{mol/L}$ in patients with PCOS and 11.58 ± 3.82 $\mu\text{mol/L}$ in controls ($p=0.002$). Patients with PCOS had a significantly higher risk for hyperhomocysteinemia compared with BMI-matched control women.

Conclusion: These data suggest that homocysteine levels are elevated in the PCOS population. Further studies are needed to characterize this relationship.

Keywords: Polycystic Ovary Syndrome, Homocysteine Blood, Cardiovascular Disease

Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrinological disorder amongst reproductive age women. The pathophysiology of PCOS is complex in that it causes a spectrum of manifestations (1-4). It is associated with a variety of comorbidities such as diabetes, hypertension, dyslipidemia, cardiovascular events and malignancies that manifest at a young age (4, 5). Preliminary investigations suggest that serum biomarkers of cardiovascular disease such as high-sensitivity C-reactive protein, homocysteine and adiponectin are abnormal in women with PCOS (6-9). Since hyperhomocysteinemia is a risk factor for cardiovascular diseases, it has been postulated that homocysteine levels are higher in PCOS patients than controls. Homocysteine is an amino acid formed by the conversion of methionine to cysteine. It is metabolized by one of two pathways: trans-sulfuration and remethylation. This process requires vitamin B as a cofactor (5-8). Normal homocysteine concentrations range between 5 and 15 $\mu\text{mol/L}$. Hyperhomocysteinemia has been classified as follows (10): mild (15 to 30 $\mu\text{mol/L}$), intermediate (30 to 100 $\mu\text{mol/L}$) and severe (>100 $\mu\text{mol/L}$). Elevations in plasma homocysteine are common and occur in five to sev-

en percent of the general population. Hyperhomocysteinemia is an independent risk factor for atherosclerotic vascular disease, cerebrovascular events and recurrent venous thromboembolism. It can occur due to genetic defects in the enzymes involved in homocysteine pathways such as methylene tetrahydrofolate reductase (MTHFR), to deficiencies in vitamin cofactors, or additional factors which include certain chronic medical conditions and drugs, such as fibrates and nicotinic acid (11-17). Several studies have investigated homocysteine levels in PCOS patients (18-28). Most have shown that women with PCOS have elevated homocysteine levels when compared with controls (19-24). Recently, Mancini et al. in their prospective case-control study on 44 patients have shown that homocysteine levels did not differ between PCOS and control women (18). Because of the complex limitations of these studies, such as a lack of uniformity in the definition of PCOS and information on levels of other cofactors, the results vary. The purpose of this paper is to evaluate homocysteine levels in the PCOS population compared with controls.

Materials and Methods

Eighty five patients with PCOS who had no ad-

Received: 17 Feb 2010, Accepted: 22 Sep 2010

* Corresponding Address: P.O.Box: 14137, Department of Obstetrics and Gynecology, Infertility and Reproductive Health Research Center (IRHRC), Shahid Beheshti University (Mc.S), Tehran, Iran
Email: sagharsalehpour@yahoo.com



Royan Institute
International Journal of Fertility and Sterility
Vol 4, No 4, Jan-Mar 2011, Pages: 168-171

ditional metabolic or cardiovascular diseases were enrolled in a prospective nonrandomized case-controlled clinical study. PCOS cases (n=85) and controls (n=83) were recruited from the Gynecology Clinic at Taleghani Hospital, Tehran, Iran between 2008-2009. All cases had a confirmed diagnosis of PCOS based on the Rotterdam diagnostic criteria: oligomenorrhoea (inter-menstrual interval greater than 42 days) and hyperandrogenism which was defined clinically as a Ferriman-Gallwey score of 8 and/or the presence of androgenic alopecia, and biochemically as a serum testosterone concentration 2.36 nmol/l and/or free androgen index 8.98 (29). The cut-off value for defining hyperhomocysteinemia was 15 $\mu\text{mol/L}$. Other causes of hyperhomocysteinemia such as deficiencies in vitamins B12, B6, folic acid, and history of chronic medical conditions which included renal failure, thyroid dysfunction, liver diseases, drugs such as fibrates and nicotinic acid and smoking were previously excluded. All control women had regular menstrual cycles. Therefore, none of the control women fulfilled any of the Rotterdam diagnostic criteria for PCOS. All control women had regular menstrual cycles and normoandrogenaemia. No confounding medications (hormonal preparations, Metformin, Simvastatin and other related medications) had been taken by any of the subjects within three months of the study in both groups. A perfect match was obtained for body mass index (BMI) between PCOS cases and controls. The study was approved by the Ethics Committee of Shahid Beheshti University of Medical Science. All subjects provided fully informed consents.

Serum homocysteine (total) levels were measured using the RIA technique (LINCO Research, St. Charles, MO, USA). All blood samples were taken following an overnight fast.

For comparisons of the pair-matched groups of PCOS cases and controls, we used paired-sample t-tests. All analyses were conducted with SPSS (version 12.0 for Windows; SPSS Inc., Chicago, IL, USA). $P < 0.05$ was considered significant.

Results

The mean age of women was 29 ± 5.9 years in the PCOS group and 27.3 ± 5.3 years in controls ($p=0.06$). The mean baseline BMI was 26.7 ± 4.2 kg/m^2 and 25.8 ± 4.1 kg/m^2 in PCOS and controls, respectively (Table 1). According to the t test there were no meaningful differences between these groups in BMI ($p=0.1$). The mean level of homocysteine was 16.25 ± 11.94 $\mu\text{mol/L}$ in patients with PCOS and 11.58 ± 3.82 $\mu\text{mol/L}$ in controls.

Paired-sample comparisons revealed that patients

with PCOS had a significantly higher risk for hyperhomocysteinemia when compared with BMI-matched control women (Table 2).

Table 1: Demographic data in patients with PCOS and controls

	PCOS (n=85)	Controls (n=83)
Age	29 ± 5.9	27.3 ± 5.3
BMI (kg/m^2)	26.7 ± 4.2	25.8 ± 4.1
Homocysteine level (mean \pm SD) $\mu\text{mol/L}$	16.25 ± 11.94	11.58 ± 3.82

All values are mean \pm SD.

Table 2: Comparison of hyperhomocysteinemia in PCOS patients and controls*

Hcy** ($\mu\text{mol/L}$)	≥ 15	< 15
PCOS (n=85)	39 (45.8%)	46 (54.1%)
Controls (n=83)	22 (26.5%)	61 (73.4%)

* Odds ratio: 2.35, 95% CI (12.65-17.35)

**Homocysteine levels

Discussion

Our data showed that serum homocysteine levels were significantly higher in PCOS women than controls. Our findings are consistent with a previous smaller study by Battaqlia et al. (30). Moreover in our review on 13 studies, with the exception of Mancini and Yilmaz, the same results were noted (20). Homocysteine has a well-known role in cardiovascular morbidity and mortality. It has primary atherogenic and prothrombotic properties. Homocysteine promotes leukocyte recruitment by upregulating monocyte chemoattractant protein-1 and interleukin-8 expression and secretion. The metabolite of homocysteine can combine with LDL-cholesterol to produce foam cells and atherosclerotic plaques. Homocysteine increases smooth muscle cell proliferation and enhances collagen production. Prothrombotic effects of homocysteine include attenuation of endothelial cell tissue plasminogen activator binding sites, activation of factor VIIa and V, inhibition of protein C and heparin sulfate, increased fibrinopeptide A and prothrombin fragments 1 and 2, increased blood viscosity, and decreased endothelial antithrombotic activity due to changes in thrombomodulin function.

Free radicals formed during the oxidation of reduced homocysteine may directly injure endothelial cells. Marked platelet aggregation may be secondary to the pro-aggregatory effects of homocysteine. Prolonged exposure of endothelial cells to homocysteine impairs the production of nitric oxide. Hyperhomocysteinemia has been linked

to myocardial infarction and recurrent coronary events, adverse outcomes after angioplasty, carotid artery stenosis, recurrent venous thrombosis, osteoporosis, dementia and silent brain infarct (31, 32). The levels of homocysteine in the PCOS population compared with controls have been studied with conflicting results.

In multiple logistic regression analysis, age and BMI were not predictors of hyperhomocysteinemia. Because of the higher rate of hyperhomocysteinemia in PCOS subjects with significantly elevated fasting insulin, we suggest that it may be secondary to the higher prevalence of insulin resistance in PCOS patients (33).

Badawy et al. in their prospective case-control study on ninety PCOS women which used a cut off level of 11 $\mu\text{mol/L}$ for a normal homocysteine level, found that 41.1% of PCOS patients and 2.9% of the control group had high homocysteine levels, which demonstrated the effect of insulin resistance on homocysteine levels (23). Kilic-Okman in a study of 29 patients with PCOS showed significant measures between the groups (33). In another similar study, the authors found that mean plasma homocysteine levels were significantly higher in the insulin-resistant PCOS patients as compared with non-insulin-resistant PCOS patients (34-37). Mancini et al. in their prospective case-control study on 44 patients showed that homocysteine levels did not differ among PCOS women and controls. In this study, they also assessed androgens, fasting glucose, insulin, leptin, fibrinogen, homocysteine, endothelin-1 and flow-mediated dilatation of the brachial artery to investigate their relationships to weight and PCOS. These researchers have suggested that weight and PCOS were two independent variables which have an effect on endothelial function (18). The lack of uniformity in the definition of PCOS and hyperhomocysteinemia as well as information on other cofactors such as BMI, fat distribution, and insulin sensitivity can explain the differences between our findings and other studies. To limit the potential confounding effect of disparate BMI between PCOS cases and controls, we adjusted for these differences in whole-group comparisons.

Insulin sensitivity was not assayed in this study, thus the relationship between plasma homocysteine level and insulin resistance was not determined. Although it was better to limit the potential for varied serum homocysteine levels during the menstrual cycle, therefore all controls and PCOS cases with regular menstrual cycles had blood taken during the follicular phase (days 2-5) of the menstrual cycle. However this was not

possible in this study due to irregular or absent menses in patients with PCOS.

Conclusion

However, the true risk of events due to hyperhomocysteinemia in women with PCOS is unknown because of the lack of prospective data in addition to few studies published in older women who have an inconsistent diagnosis of PCOS (38-40). Therefore, prospective studies with a well-defined PCOS population are required. Screening for hyperhomocysteinemia before the use of oral contraceptive pills and diagnosis at a young age maybe beneficial. Therapeutic lifestyle changes with diet and exercise interventions and associated cardiovascular risk factors, including insulin resistance, hypertension, and dyslipidemia should be considered.

Acknowledgments

The authors wish to thank the Endocrine and Metabolism Research Institute at Shahid Beheshti University, Tehran, Iran for supporting this project. We are sincerely grateful to Dr. Mohsen Hedayati for his tremendous assistance. We would like to express our appreciation to all the patients who cooperated in this study.

There is no conflict of interest in this article.

References

1. Haugaard LK, Vestergaard H, Skouby SO. Polycystic ovary syndrome and comorbidity. *Ugeskr Laeger*. 2010; 172(3): 199-202.
2. Mak W, Dokras A. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. *Semin Thromb Hemost*. 2009; 35(7): 613-620.
3. Salehpour S, Aghaee A. The effect of ovarian drilling on the fertility of patients with PCOS. *Pajohand*. 1999; 4(20): 423-428.
4. Salehpour S, Saadt N, Ashrafi M, Emami H. The effect of metformin therapy on menstrual function in PCOS. *Med J Iran Hosp*. 2002; 15(1): 20-22.
5. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. *Clin Endocrinol (Oxf)*. 2000; 52(5): 595-600.
6. Uland PM, Refsum H. Plasma homocysteine, a risk factor for vascular diseases. *J Lab Clin Med*. 1989; 114(5): 473-501.
7. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. *Acta Obstet Gynecol Scand*. 1992; 71(8): 599-604.
8. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. *Arterioscler Thromb Vasc Biol*. 1995; 15(7): 821-826.
9. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. *Ann Intern Med*. 1997; 126(1): 32-35.
10. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sat-

- tar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. *J Clin Endocrinol Metab.* 2001; 86(6): 2453-2455.
11. Baccarelli A, Zanobetti A, Martinelli I, Grillo P, Hou L, Lanzani G et al. Air pollution, smoking and plasma homocysteine. *Environ Health Perspect.* 2007; 115(2): 176-181.
 12. Cabarkapa V, Stosić Z, Zeravica R, Ilincić B. The importance of homocysteine measurement in chronic renal failure. *Med Preg.* 2007; 60 suppl 2: 81-83.
 13. Dierkes J, Westphal S, Luley C. The effects of fibrates and other lipid lowering drugs on plasma homocysteine levels. *Expert Opin Drug Saf.* 2004; 3(2): 101-111.
 14. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. *Atherosclerosis.* 2003; 171(1): 87-96.
 15. Orio F Jr, Palomba S, Di Biase S, Colao A, Tauchmanova L, Savastano S, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with PCOS. *J Clin Endocrinol Metab.* 2003; 88(2): 673-679.
 16. D'Angelo A, Coppola A, Madonna P, Fermo I, Pagano A, Mazzola G, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events. *Thromb Haemost.* 2000; 83(4): 563-570.
 17. Vermeulen EG, Stehouwer CD, Twisk JW, van den Berg M, de Jong SC, Mackaay AJ, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. *Lancet.* 2000; 355(9203): 517-522.
 18. Mancini F, Cianciosi A, Reggiani GM, Facchinetti F, Battaglia C, de Aloysio D. Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. *Fertil Steril.* 2009; 91(6): 2537-2544.
 19. Oktom M, Ozcimen EE, Uckuyu A, Esinler I, Pamuk B, Bayraktar N, et al. Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. *Fertil Steril.* 2009; 91(6): 2545-2550.
 20. Salehpour S, Taherzade P, Neisani Samani E. Leptin, Ghrelin, Adiponectin, Homocysteine and Insulin resistance related to PCOS. *International Journal of Fertility and Sterility (IJFS).* 2008; 3(3): 101-104.
 21. Yilmaz N, Pektas M, Tonguc E, Kilic S, Gulerman C, Gungor T, et al. The correlation of plasma homocysteine with insulin resistance in polycystic ovary syndrome. *J Obstet Gynaecol Res.* 2008; 34(3): 384-391.
 22. Atamer A, Demir B, Bayhan G, Atamer Y, Ilhan N, Akkuş Z. Serum levels of leptin and homocysteine in women with polycystic ovary syndrome and its relationship to endocrine, clinical and metabolic parameters. *J Int Med Res.* 2008; 36(1): 96-105.
 23. Badawy A, State O, El Gawad SSh, El Aziz OA. Plasma homocysteine and PCOS: the missed link. *Eur Obstet Gynecol Reprod Biol.* 2007; 131(1): 68-72.
 24. de la Calle M, Gallardo T, Diestro MD, Hernanz A, Pérez E, Fernández-Miranda C. Increased homocysteine levels in polycystic ovary syndrome. *Med Clin.* 2007; 129(8): 292-294.
 25. Yilmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Törüner F, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. *Gynecol Endocrinol.* 2005; 20(5): 258-263.
 26. Guzelmeric K, Alkan N, Pirimoglu M, Unal O, Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. *Gynecol Endocrinol.* 2007; 23(9): 505-510.
 27. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. *Gynecol Obstet Invest.* 2002; 53(3): 157-162.
 28. Yarali H, Yildirim A, Aybar F, Kabakçi G, Bükülmez O, Akgül E, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. *Fertil Steril.* 2001; 76(3): 511-516.
 29. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod.* 2004; 19(1): 41-47.
 30. Battaglia C, Mancini F, Cianciosi A, Busacchi P, Facchinetti F, Marchesini GR, et al. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. *Obstet Gynecol.* 2008; 111(2 Pt 1): 385-95.
 31. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med.* 1998; 338(15): 1042-1050.
 32. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. *Int J Epidemiol.* 1995; 24(4): 704-709.
 33. Kilic-Okman T, Guldiken S, Kucuk M. Relationship between homocysteine and insulin resistance in women with polycystic ovary syndrome. *Endocr J.* 2004; 51(5): 505-508.
 34. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in PCOS: does it correlate with insulin resistance and ethnicity? *Clin Endocrinol.* 2004; 60(5): 560-567.
 35. Schachter M, Raziell A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. *Hum Reprod.* 2003; 18(4): 721-727.
 36. McCarty MF. Insulin secretion as a potential determinant of homocysteine levels. *Med Hypotheses.* 2000; 55(5): 454-455.
 37. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2006; 91(4): 1357-1363.
 38. Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb PET al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). *J Clin Pathol.* 2005; 58(2): 151-154.
 39. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. *J Clin Endocrinol Metab.* 2007; 92(12): 4609-4614.
 40. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. *Rev Obstet Gynecol.* 2009; 2(4): 232-239.